Monthly Archives: September 2016

Thus, ziv-aflibercept is now FDA approved for second-line use in combination with FOLFIRI or irinotecan in patients with disease progression on oxaliplatin. There are no studies in surgical patients as of yet. Another oral agent, regorafenib, has also been investigated … Continue reading →

In preliminary testing, respondents completed the battery of tests in less than 15 minutes. At baseline the research assistant administer the questionnaire with the use of visual aids to help with answering the questions. When obtaining the consent, patients will … Continue reading →

A detailed description of this cognitive and neurobiological profile has been elusive, due to a combination of both state-and Abiraterone manufacturer trait-related changes in bipolar disorder. In principle, three distinct profiles may exist. An abnormality may be a state-related deficit … Continue reading →

The biomarker advantage of pramipexole, however, did not translate into a clear, clinically meaningful advantage. Indeed, although patients on pramipexole had a lower incidence of complications, patients randomized to initial levodopa had an early and sustained improvement in function, and … Continue reading →

Targeting drug-loaded liposomes, in addition to enhancing their therapeutic activity, enhances tumor detection and response monitoring when they are coloaded with an imaging agent. Addition of transferrin to 10B plus iodine contrast agent coloaded liposomes allowed a 3.6-fold higher 10B … Continue reading →

Louis, MO), was made up to four different concentrations (0.1, 1, 10, and 100 μmol/L) in aCSF and kept frozen until use. The solutions were delivered through an electrical syringe pump (Instech, Plymouth Meeting, PA) calibrated to deliver a total volume … Continue reading →

This study also highlights the type of thought that should go into determining the evaluation for a study. Since minor depression was an unknown entity at the time, one of the key questions was: how stable is this entity over … Continue reading →

Selecting patients for more intense radiation therapy will require a better understanding of the biology of tumors that tend to recur locally as opposed to distantly and the deployment of techniques to achieve this intensification of radiation therapy safely and … Continue reading →

While technological advances in capacity for sequencing analysis have exceeded the benchmark measure of computing power, Moore’s Law, there is no doubt that this success has been largely tied to computational advances. The transfer of this knowledge from the laboratory … Continue reading →

Andreasson et al89 prospectively followed up a cohort of Swedish conscripts who had been interviewed about their cannabis use at age 18 to 20 years and found an elevated relative risk (RR) for schizophrenia amongst users compared to nonusers (RR=2.4). … Continue reading →